【报告导读】1.核心产品海外放量超预期,25年指引经营性现金流转正。2.血液瘤领域领先地位进一步巩固。3.多项自主研发管线迎来价值拐点。核心观点事件:2025年4月29日,百济神州发布2024年年度业绩报告,2024全年公司实现营业收入272.14亿元(+56.19%);归母净亏损49.78亿元,亏损同比收窄25.87%;扣非归母净亏损53.79亿元,亏损同比收窄44.44%; 经营性现金流-...
Source Link【报告导读】1.核心产品海外放量超预期,25年指引经营性现金流转正。2.血液瘤领域领先地位进一步巩固。3.多项自主研发管线迎来价值拐点。核心观点事件:2025年4月29日,百济神州发布2024年年度业绩报告,2024全年公司实现营业收入272.14亿元(+56.19%);归母净亏损49.78亿元,亏损同比收窄25.87%;扣非归母净亏损53.79亿元,亏损同比收窄44.44%; 经营性现金流-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.